Quest Diagnostics Incorporated (DGX) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong FCF ⢠Aboveâaverage leverage ⢠Tight liquidity Solid profitability and strong free cash flow support dividends, but tight liquidity, aboveâaverage leverage and a large intangible asset base raise balanceâsheet risk while valuation (~P/E 23.4, EV/EBIT ~19) is not cheap.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Near support ⢠Moderate volatility Support Level: $199â$200 Resistance Level: $212 DGX is in a short-term downtrend over the last month, consolidating between support around $199â$200 and resistance near $212, with moderate volatility around the lateâFebruary peak.
Sentiment & News
Key News Insights: ⢠AI patient tool ⢠Board/executive adds ⢠Institutional accumulation Quest Diagnostics is advancing AI-driven patient tools and strategic leadership while attracting institutional buying and analyst support despite some insider selling and a modest post-earnings share decline.
AI Summary
Quest Diagnostics has shifted from a defensive cash-generator to an executionâsensitive growth platformâits valuation now hinges on successful MRD/advanced diagnostics commercialization, Nova integration, and hospital JV scale rather than just steady cash returns. Monitor three specific proof points over the next 12â18 monthsâpayer coverage and clinical uptake for MRD, visible Nova-driven margin inflection, and PAMA clarity/leverage stabilityâas misses on any would likely produce sharp multiple compression.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |